Clinical Trial Update: Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the safety and immunogenicity of two doses of aH5N1 Monovalent H5N1 Influenza Vaccine in adults and elderly subjects with and without …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza

Drugs mentioned

• aH5N1 Monovalent H5N1 Influenza Vaccine (H5N1 influenza vaccine, monovalent)

Snippet

Sponsor: Seqirus | Conditions: Influenza, Human, Flu, Human | Phase 3 | Status: COMPLETED